Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
05
2020
accepted:
29
06
2020
entrez:
21
7
2020
pubmed:
21
7
2020
medline:
22
9
2020
Statut:
epublish
Résumé
The Japan Chronic Kidney Disease Database (J-CKD-DB) is a nationwide clinical database of patients with chronic kidney disease (CKD) based on electronic health records. The objective of this study was to assess the prevalence of anemia and the utilization rate of erythropoiesis-stimulating agents (ESAs) in Japanese patients with CKD. In total, 31,082 adult outpatients with estimated glomerular filtration rates of 5-60 ml/min/1.73 m2 in seven university hospitals were included this analysis. The proportions of patients with CKD stages G3b, G4, and G5 were 23.5%, 7.6%, and 3.1%, respectively. The mean (standard deviation) hemoglobin level of male patients was 13.6 (1.9) g/dl, which was significantly higher than the mean hemoglobin level of female patients (12.4 (1.6) g/dl). The mean (standard deviation) hemoglobin levels were 11.4 (2.1) g/dl in patients with CKD stage G4 and 11.2 (1.8) g/dl in patients with CKD stage G5. The prevalences of anemia were 40.1% in patients with CKD stage G4 and 60.3% in patients with CKD stage G5. Logistic regression analysis showed that diagnoses of CKD stage G3b (adjusted odds ratio [95% confidence interval]: 2.32 [2.09-2.58]), G4 (5.50 [4.80-6.31]), and G5 (9.75 [8.13-11.7]) were associated with increased prevalence of anemia. The utilization rates of ESAs were 7.9% in patients with CKD stage G4 and 22.4% in patients with CKD stage G5. We determined the prevalence of anemia and utilization rate of ESAs in Japanese patients with CKD using data from a nationwide cohort study.
Sections du résumé
BACKGROUND
The Japan Chronic Kidney Disease Database (J-CKD-DB) is a nationwide clinical database of patients with chronic kidney disease (CKD) based on electronic health records. The objective of this study was to assess the prevalence of anemia and the utilization rate of erythropoiesis-stimulating agents (ESAs) in Japanese patients with CKD.
METHODS
In total, 31,082 adult outpatients with estimated glomerular filtration rates of 5-60 ml/min/1.73 m2 in seven university hospitals were included this analysis. The proportions of patients with CKD stages G3b, G4, and G5 were 23.5%, 7.6%, and 3.1%, respectively.
RESULTS
The mean (standard deviation) hemoglobin level of male patients was 13.6 (1.9) g/dl, which was significantly higher than the mean hemoglobin level of female patients (12.4 (1.6) g/dl). The mean (standard deviation) hemoglobin levels were 11.4 (2.1) g/dl in patients with CKD stage G4 and 11.2 (1.8) g/dl in patients with CKD stage G5. The prevalences of anemia were 40.1% in patients with CKD stage G4 and 60.3% in patients with CKD stage G5. Logistic regression analysis showed that diagnoses of CKD stage G3b (adjusted odds ratio [95% confidence interval]: 2.32 [2.09-2.58]), G4 (5.50 [4.80-6.31]), and G5 (9.75 [8.13-11.7]) were associated with increased prevalence of anemia. The utilization rates of ESAs were 7.9% in patients with CKD stage G4 and 22.4% in patients with CKD stage G5.
CONCLUSIONS
We determined the prevalence of anemia and utilization rate of ESAs in Japanese patients with CKD using data from a nationwide cohort study.
Identifiants
pubmed: 32687544
doi: 10.1371/journal.pone.0236132
pii: PONE-D-20-14790
pmc: PMC7371174
doi:
Substances chimiques
Hemoglobins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0236132Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nephrol Dial Transplant. 2018 Aug 1;33(8):1373-1379
pubmed: 29045728
Kidney Int Suppl (2011). 2013 Jan;3(1):19-62
pubmed: 25018975
Int J Nephrol Renovasc Dis. 2013;6:1-13
pubmed: 23319870
Nephrol Dial Transplant. 2004 May;19 Suppl 2:ii1-47
pubmed: 15206425
Kidney Int. 2005 Jun;67(6):2089-100
pubmed: 15882252
Clin Exp Nephrol. 2019 Feb;23(2):215-222
pubmed: 30168046
Clin Exp Nephrol. 2009 Dec;13(6):621-30
pubmed: 19513802
Am J Manag Care. 2010 Mar;16 Suppl Issues:S59-66
pubmed: 20297873
Ther Apher Dial. 2012 Dec;16(6):529-40
pubmed: 23190512
J Am Coll Cardiol. 2001 Oct;38(4):955-62
pubmed: 11583864
Ther Apher Dial. 2010 Jun;14(3):240-75
pubmed: 20609178
Am J Kidney Dis. 2006 May;47(5 Suppl 3):S11-145
pubmed: 16678659
Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii142-ii150
pubmed: 28201668
Am J Kidney Dis. 2008 Apr;51(4 Suppl 2):S46-55
pubmed: 18359408
Clin Exp Nephrol. 2011 Apr;15(2):248-57
pubmed: 21234785
Clin Kidney J. 2018 Feb;11(1):99-107
pubmed: 29423209
Methods Inf Med. 2011;50(2):131-9
pubmed: 21206962
PLoS One. 2017 Feb 2;12(2):e0171106
pubmed: 28151999
J Am Coll Cardiol. 2001 Jun 1;37(7):1775-80
pubmed: 11401110
Diabet Med. 2010 Sep;27(9):1017-23
pubmed: 20722675
Diabetol Int. 2017 Jun 27;8(4):375-382
pubmed: 30603343
Sci Rep. 2017 Sep 14;7(1):11530
pubmed: 28912532
Clin Exp Nephrol. 2009 Dec;13(6):537-66
pubmed: 19960305
Clin Exp Nephrol. 2016 Aug;20(4):595-602
pubmed: 26519375
Medicine (Baltimore). 2016 Jun;95(24):e3872
pubmed: 27310973
Am J Kidney Dis. 1994 Nov;24(5):777-84
pubmed: 7977319
PLoS One. 2014 Jan 02;9(1):e84943
pubmed: 24392162
Sci Rep. 2020 Apr 30;10(1):7351
pubmed: 32355258
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
J Am Soc Nephrol. 2005 Nov;16(11):3403-10
pubmed: 16162813
BMC Public Health. 2008 Apr 11;8:117
pubmed: 18405348
Am J Kidney Dis. 2019 Feb;73(2):206-217
pubmed: 30348535
Circulation. 2003 Oct 28;108(17):2154-69
pubmed: 14581387
Am J Nephrol. 2014;39(4):288-96
pubmed: 24714513